KRTX News and Press, Karuna Therapeutics Inc. From 11/16/23

2023-11-16 17:03:01 ET More on Karuna Therapeutics Karuna Therapeutics: Rewiring The Schizophrenia Paradigm - A Novel Leap Beyond Dopamine Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call Transcript Karuna Therapeutics: KarXT Could Become A New Stand...

Results demonstrate KarXT was not associated with clinically meaningful increases in blood pressure in adults with schizophrenia KarXT demonstrated a mean change from baseline to week 8 in 24-hour ambulatory systolic blood pressure of -0.59 mmHg, the primary endpoint in the trial ...

2023-11-06 00:32:05 ET Summary Karuna Therapeutics focuses on developing therapies that target muscarinic cholinergic receptors to treat psychosis and cognitive impairment in CNS disorders. The Company's lead asset, KarXT, has shown promising efficacy in phase III studies and has ...

2023-11-05 01:51:22 ET Karuna Therapeutics, Inc. (KRTX) Q3 2023 Earnings Conference Call November 2, 2023, 08:00 AM ET Company Participants Alexis Smith - Head of Corporate Affairs and IR Bill Meury - President and CEO Jason Brown - CFO Andrew Miller - Founde...

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

2023-11-02 06:47:03 ET More on Karuna Therapeutics For further details see: Karuna Therapeutics GAAP EPS of -$3.16 misses by $0.40

Submitted New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for KarXT for the treatment of schizophrenia in the third quarter of 2023 Initiated the Phase 3 ADEPT-2 and ADEPT-3 trials evaluating KarXT for the treatment of psychosis in Alzheimer’s disease in t...

Karuna Therapeutics Inc. (KRTX) is expected to report $-2.74 for Q3 2023

2023-11-02 03:11:38 ET Summary Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizophrenia show that the 50 mg dose beat placebo on the primary endpoint. The 15 mg dose of brilaroxazine was numerically superior to placebo on the p...

2023-11-01 12:44:18 ET More on Karuna Therapeutics Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) For further details see: Karuna Therapeutics Q3 2023 Earni...